Foregoing intracardiac electrophysiologic mapping was as good as conventional cryoablation with pulmonary vein (PV) mapping in the AVATAR-HF* study, suggesting that a simplified procedure could produce the same outcomes for lower costs.
Use of uninterrupted edoxaban during catheter ablation for atrial fibrillation (AF) shows comparable safety and efficacy as uninterrupted vitamin K antagonists (VKAs), according to the ELIMINATE-AF trial presented at EHRA 2019.
Patients on the anticoagulant drug edoxaban could safely continue their treatment while undergoing certain procedures, with a low incidence of bleeding and cardiovascular events reported in the prospective EMIT AF/VTE* study.
Remote monitoring (RM) reduced hospitalization rates in patients with heart failure (HF) and implanted cardioverter-defibrillator (ICD) or cardiac resynchronization therapy defibrillator (CRT-D), according to data from the RESULT* trial presented at EHRA 2019.
Patients who have recently experienced atrial fibrillation (AF) could benefit from treatment with upfront rate-control medication rather than undergoing immediate cardioversion to restore sinus rhythm, according to The Netherlands-based RACE 7 ACWAS* trial.
A two-part tilt training programme designed to retrain the autonomic nervous system (ANS) to respond correctly to move to an upright position effectively prevented reflex syncope (RS) or fainting episodes, offering patients an improved quality of life (QoL) and ability to return to work, according to data presented at EHRA 2019.
Use of high doses of the dihydropyridine nifedipine was associated with a higher risk of out-of-hospital cardiac arrest (OHCA) than nonuse of dihydropyridines, according to data from two large registries under the ESCAPE-NET* presented at EHRA Congress 2019.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.